ATE243230T1 - Gelierte magnetisch markierte molekularsysteme als nmr-bilderzeugungsmittel - Google Patents

Gelierte magnetisch markierte molekularsysteme als nmr-bilderzeugungsmittel

Info

Publication number
ATE243230T1
ATE243230T1 AT96935209T AT96935209T ATE243230T1 AT E243230 T1 ATE243230 T1 AT E243230T1 AT 96935209 T AT96935209 T AT 96935209T AT 96935209 T AT96935209 T AT 96935209T AT E243230 T1 ATE243230 T1 AT E243230T1
Authority
AT
Austria
Prior art keywords
gelated
imaging agent
sequence
nmr imaging
magnetically labeled
Prior art date
Application number
AT96935209T
Other languages
English (en)
Inventor
Herve Tournier
Sibylle Pochon
Bernard Lamy
Original Assignee
Bracco Research Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8221811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE243230(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bracco Research Sa filed Critical Bracco Research Sa
Application granted granted Critical
Publication of ATE243230T1 publication Critical patent/ATE243230T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1866—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
AT96935209T 1995-11-01 1996-10-31 Gelierte magnetisch markierte molekularsysteme als nmr-bilderzeugungsmittel ATE243230T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95810689 1995-11-01
PCT/IB1996/001174 WO1997016474A1 (en) 1995-11-01 1996-10-31 Targeted magnetically labeled molecular marker systems for the nmr imaging

Publications (1)

Publication Number Publication Date
ATE243230T1 true ATE243230T1 (de) 2003-07-15

Family

ID=8221811

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96935209T ATE243230T1 (de) 1995-11-01 1996-10-31 Gelierte magnetisch markierte molekularsysteme als nmr-bilderzeugungsmittel

Country Status (6)

Country Link
US (1) US5910300A (de)
EP (1) EP0800545B2 (de)
JP (1) JP4018141B2 (de)
AT (1) ATE243230T1 (de)
DE (1) DE69628731T3 (de)
WO (1) WO1997016474A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE243230T1 (de) * 1995-11-01 2003-07-15 Bracco Research Sa Gelierte magnetisch markierte molekularsysteme als nmr-bilderzeugungsmittel
US20070036722A1 (en) * 1996-10-28 2007-02-15 Pal Rongved Separation processes
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
AU733495B2 (en) 1996-10-28 2001-05-17 Nycomed Imaging As Improvements in or relating to diagnostic/therapeutic agents
IL138093A0 (en) * 1998-03-31 2001-10-31 Du Pont Pharm Co Pharmaceuticals for the imaging of angiogenic disorders
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
EP1140864A2 (de) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Pharmazeutische zusammensetzungen, vitronectinrezeptor antagonisten enthaltend
CA2727746A1 (en) 1998-12-18 2000-06-22 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6432409B1 (en) * 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response
US9289487B2 (en) * 1999-09-14 2016-03-22 Antigen Express, Inc. II-key/antigenic epitope hybrid peptide vaccines
EP1289565B1 (de) 2000-06-02 2015-04-22 Bracco Suisse SA Arzneimitteln zur zielgerichtung von endothelzellen
WO2002036073A2 (en) * 2000-11-02 2002-05-10 Smithkline Beecham Corporation Receptor antagonist-lipid conjugates and delivery vehicles containing same
US20040058458A1 (en) * 2002-04-18 2004-03-25 The Regents Of The University Of Michigan Modulated chemical sensors
US8697029B2 (en) 2002-04-18 2014-04-15 The Regents Of The University Of Michigan Modulated physical and chemical sensors
WO2004030616A2 (en) 2002-09-17 2004-04-15 Antigen Express, Inc. Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES
US7179645B2 (en) 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
US9695251B2 (en) 2003-10-31 2017-07-04 The Regents Of The University Of California Activatable cell penetrating peptides with quenched fluorophores
US7431915B2 (en) 2003-10-31 2008-10-07 The Regents Of The University Of California Peptides whose uptake by cells is controllable
US7985401B2 (en) 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
US20050260137A1 (en) * 2004-05-18 2005-11-24 General Electric Company Contrast agents for magnetic resonance imaging
US20080019918A1 (en) * 2004-09-10 2008-01-24 Takao Aoki Medicinal Preparation
ES2356016T3 (es) * 2006-03-09 2011-04-04 Cambridge Enterprise Limited Composiciones antibióticas novedosas.
US9738745B2 (en) 2006-06-29 2017-08-22 Life Technologies As Particles containing multi-block polymers
JP5364589B2 (ja) 2006-12-11 2013-12-11 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 診断および治療適用用フィブリン結合ペプチドコンジュゲート
US9068977B2 (en) * 2007-03-09 2015-06-30 The Regents Of The University Of Michigan Non-linear rotation rates of remotely driven particles and uses thereof
EP2344191A4 (de) * 2008-09-02 2013-02-13 Antigen Express Inc Humane papillomavirus / li-key-hybride und anwendungsverfahren
EP2391748A4 (de) * 2009-01-28 2012-08-01 Antigen Express Inc Li-key-hybridpeptide zur modulation der immunreaktion auf influenza
WO2011008996A2 (en) * 2009-07-15 2011-01-20 The Regents Of The University Of California Peptides whose uptake in cells is controllable
US8846331B2 (en) 2010-08-27 2014-09-30 The Regents Of The University Of Michigan Asynchronous magnetic bead rotation sensing systems and methods
WO2012142179A2 (en) 2011-04-11 2012-10-18 The Regents Of The University Of Michigan Magnetically induced microspinning for super-detection and super-characterization of biomarkers and live cells
US9797817B2 (en) 2012-05-03 2017-10-24 The Regents Of The University Of Michigan Multi-mode separation for target detection
WO2014120837A2 (en) 2013-01-29 2014-08-07 The Regents Of The University Of California Pretargeted activatable cell penetrating peptide with intracellulary releaseable prodrug
WO2014120974A1 (en) 2013-01-30 2014-08-07 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
US9983110B2 (en) 2013-11-04 2018-05-29 The Regents Of The University Of Michigan Asynchronous magnetic bead rotation (AMBR) microviscometer for analysis of analytes
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
US10596259B2 (en) 2015-05-20 2020-03-24 The Regents Of The University Of California Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4070246A (en) * 1976-04-09 1978-01-24 Abbott Laboratories Reactive matrices
US4157323A (en) * 1976-06-09 1979-06-05 California Institute Of Technology Metal containing polymeric functional microspheres
US4628037A (en) * 1983-05-12 1986-12-09 Advanced Magnetics, Inc. Binding assays employing magnetic particles
CA1268208A (en) * 1984-08-10 1990-04-24 Truman Brown Magnetic micro-particles as contrast agents in nuclear magnetic resonance imaging
US4762915A (en) * 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
US5271927A (en) * 1986-02-13 1993-12-21 Celltech Limited Antibody conjugates with macrocyclic ligands
US5069216A (en) * 1986-07-03 1991-12-03 Advanced Magnetics Inc. Silanized biodegradable super paramagnetic metal oxides as contrast agents for imaging the gastrointestinal tract
US5284646A (en) * 1986-07-03 1994-02-08 Advanced Magnetics Inc. Hepatocyte specific receptor mediated endocytosis type magnetic resonance imaging contrast agents
US4827945A (en) * 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US5314679A (en) * 1986-07-03 1994-05-24 Advanced Magnetics Inc. Vascular magnetic resonance imaging agent comprising nanoparticles
JPH0720857B2 (ja) * 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
US4986979A (en) * 1989-03-14 1991-01-22 Neorx Corporation Imaging tissue sites of inflammation
NZ314680A (en) * 1989-05-09 2000-08-25 Ortho Pharma Corp Treating localised infection or inflammation with a therapeutically conjugated chemotactic peptide
US5395609A (en) * 1989-06-19 1995-03-07 Antisoma Limited Synthetic peptides for use in tumor detection
JP2978187B2 (ja) * 1989-11-02 1999-11-15 日本ケミカルリサーチ株式会社 修飾スーパーオキサイドディスムターゼの製造法
US5552525A (en) * 1991-02-08 1996-09-03 Diatech Inc. Technetium-99m labeled peptides for imaging inflammation
US5370901A (en) * 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
US5464696A (en) * 1992-08-13 1995-11-07 Bracco International B.V. Particles for NMR imaging
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
DE4309333A1 (de) * 1993-03-17 1994-09-22 Silica Gel Gmbh Superparamagnetische Teilchen, Verfahren zu ihrer Herstellung und Verwendung derselben
EP0689430B1 (de) * 1993-03-17 1997-08-13 Silica Gel Ges.M.B.H Superparamagnetische teilchen, verfahren zu ihrer herstellung und verwendung derselben
US5516703A (en) * 1993-08-20 1996-05-14 The University Of Utah Coating of hydrophobic surfaces to render them protein resistant while permitting covalent attachment of specific ligands
ATE243230T1 (de) * 1995-11-01 2003-07-15 Bracco Research Sa Gelierte magnetisch markierte molekularsysteme als nmr-bilderzeugungsmittel

Also Published As

Publication number Publication date
WO1997016474A1 (en) 1997-05-09
JPH10512617A (ja) 1998-12-02
DE69628731D1 (de) 2003-07-24
US5910300A (en) 1999-06-08
EP0800545B1 (de) 2003-06-18
DE69628731T3 (de) 2012-09-20
EP0800545B2 (de) 2011-03-02
EP0800545A1 (de) 1997-10-15
DE69628731T2 (de) 2004-04-29
JP4018141B2 (ja) 2007-12-05

Similar Documents

Publication Publication Date Title
ATE243230T1 (de) Gelierte magnetisch markierte molekularsysteme als nmr-bilderzeugungsmittel
CA1304293C (en) Immunoconjugates and methods for their use in tumor therapy
EP0259904B1 (de) Antikrebstherapie und zytotoxische Arzneimittel für deren Implementation
WO1998018497A3 (en) Contrast agents
DE3872741T (de)
AU5076799A (en) Trifunctional reagent for conjugation to a biomolecule
CA2046654A1 (en) Radiolabeled proteins for diagnostic or therapeutic use
DE69535094T2 (de) Proteinmarkierung mit radioaktivem phospor und gezielte radiotherapie
US4883862A (en) Mercaptosuccinyl glycyl-glycyl-glycine a complex thereof with Tc-99m, and methods of making the same
ATE192047T1 (de) Bicylclische, polyazamakrocyclocarbonsäure- komplexe, konjugate, herstellung und verwendung als kontraststoffe
IL104060A0 (en) Bicyclopolyazamacrocyclophosphonic acids,their complexes and conjugates,for use as contrast agents,and processes for their preparation
ES2096040T3 (es) Nuevo reactivo para la representacion grafica de los tumores y su terapia.
US5104637A (en) Radio labeled dihematophorphyrin ether and its use in detecting and treating neoplastic tissue
BR0207327A (pt) Amino derivados de biotina e seus conjugados com agentes quelantes macrocìclicos
DE69724761D1 (de) Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat
IL117564A (en) Pharmaceutical and diagnostic compositions containing lysine derivatives
ATE89567T1 (de) Konjugate von vinblastin und seine derivate, verfahren zur herstellung derselben und diese konjugate enthaltende pharmazeutische zusammensetzungen.
AU8144894A (en) Biphenyl iodinated derivatives and their diagnostic use
CA2103553A1 (en) Bicyclopolyazamacrocyclocarboxylic acid complexes their conjugates, processes for their preparation, and use as radiopharmaceuticals
AU604687B2 (en) D-gl conjugate therapy
Zubieta The coordination chemistry of technetium and rhenium and applications to nuclear medicine. Final report
CA2326720A1 (en) Hemoglobin-haptoglobin complexes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties